Biocon wins European Commission authorisation for oncology biosimilar
In short
Biocon got European Commission market approval for a biosimilar used in breast cancer treatment. The drug, pertuzumab, is now Biocon’s fifth oncology biosimilar approved in Europe and the United States.
More approvals can help the company expand its oncology business abroad.
What the reporting says
Biocon received European Commission market authorisation for a biosimilar used in breast cancer treatment, according to a publisher-supplied market summary. The approval makes pertuzumab Biocon’s fifth oncology biosimilar approval across Europe and the United States, and it adds to the company’s global oncology portfolio. The development is presented as a regulatory step for Biocon in key international markets.
Why it matters
Biocon received European Commission market authorisation for a biosimilar for breast cancer treatment, with pertuzumab becoming its fifth oncology biosimilar approved in Europe and the United States. The approval strengthens the company’s global oncology portfolio and adds another regulatory milestone in key international markets.